1. Adu A, Armour CL. Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime. Drugs. 1995;50(3):423–39.
2. Katzung B, Trevor A. Basic and clinical pharmacology. 13th ed. New York: McGraw-Hill; 2014.
3. Monte SV, Prescott WA, Johnson KK, Kuhman L, Paladino JA. Safety of ceftriaxone sodium at extremes of age. Expert Opin Drug Saf. 2008;7(5):515–23.
4. US Food and Drug Administration. Information for healthcare professionals: ceftriaxone (marketed as Rocephin). 2007.
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm134328.htm
. Accessed 20 Apr 2016.
5. US Food and Drug Administration. Information for healthcare professionals: ceftriaxone (marketed as Rocephin). 2009.
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm084263.htm
. Accessed 20 Apr 2016.